Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

Aim: The objectives were to investigate the differences in per patient per month (PPPM) healthcare resource utilization (HCRU) and costs among commercially insured and Medicare Advantage patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (mBC) who exp...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Clara Lam, Brandon Diessner, Katherine Andrade, Sydnie Stackland, Leah Park, Sandhya Mehta, Feng Lin, Winghan Jackie Kwong
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Becaris Publishing Limited 2024-04-01
Serie:	Journal of Comparative Effectiveness Research
Soggetti:	breast cancer costs hcru her2 progression
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!